Rapid PD-L1 detection in tumors with PET using a highly specific peptide

Area of Science:

• Oncology
• Immunology
• Radiochemistry

Background:

• Molecular imaging is crucial for understanding the tumor immune microenvironment and optimizing immunotherapies.
• Few imaging agents rapidly assess targets for immunomodulatory therapies.
• Programmed death ligand 1 (PD-L1) is a key immune checkpoint overexpressed in cancers, contributing to immune suppression and predicting response to PD-1/PD-L1 therapies.

Purpose of the Study:

• To develop and evaluate a novel, highly specific peptide-based positron emission tomography (PET) imaging agent for detecting tumor PD-L1 expression.
• To assess the potential of this agent to guide immunotherapeutic strategies.

Main Methods:

• Docking studies to determine the binding modes of the peptide WL12 to PD-L1.
• Development of a copper-64 labeled WL12 ([64Cu]WL12) radiotracer.
• In vitro and in vivo evaluation using PET imaging, biodistribution, and blocking studies.

Main Results:

• The [64Cu]WL12 agent demonstrated high specificity for detecting tumor PD-L1 expression.
• The radiotracer allows for rapid imaging, fitting within a standard clinical workflow of 60 minutes post-administration.
• Successful in vitro and in vivo validation of the imaging agent's performance.

Conclusions:

• The developed [64Cu]WL12 PET imaging agent is a promising tool for specifically and rapidly detecting tumor PD-L1 expression.
• This agent can potentially guide personalized immunotherapeutic strategies by providing timely information on PD-L1 status.
• The rapid imaging capability enhances its clinical applicability in cancer treatment.